Symvivo Corporation, a clinical-stage biotechnology company advancing a proprietary bacTRL™ gene delivery platform, announced today that it has entered into a research collaboration with Janssen Biotech, Inc. (Janssen), one of the Pharmaceutical Companies of Johnson & Johnson. Under the terms of the agreement, Janssen will have the exclusive option to research, develop and commercialize novel biological therapeutic candidates based on Symvivo’s bacTRL™ platform technology. The agreement was facilitated by Johnson & Johnson Innovation.

“We are gratified to be collaborating with Janssen on this important research,” said Lloyd Mackenzie, President and Chief Operating Officer at Symvivo. “This agreement continues to expand novel applications for the bacTRL™ platform.”

Canadian Media:

Chantal Allan
Sam Brown Inc. Healthcare Communications
T: 613-319-4384 (CAN)
T: 805-242-3080 (US)
E: chantalallan@sambrown.com


US Media:

Mike Beyer
Sam Brown Inc. Healthcare Communications
T: 312-961-2502
E: mikebeyer@sambrown.com